FierceBiotech 2025-12-15 Kyverna gains clear view to first CAR-T approval for autoimmune disease after 'truly remarkable' SPS readout
FierceBiotech 2025-12-15 Beyond the ADC Hype: Innovation is accelerating through bispecifics and dual payload strategies
FierceBiotech 2025-12-13 GAO probe finds understaffed FDA putting some medical device recall work on the 'back burner'
FierceBiotech 2025-12-12 Obesity biotech Zealand seeks partners to ‘take therapies directly to the brain’
FierceBiotech 2025-12-12 Cycle seizes struggling Applied Tx, picking up rare disease biotech for pennies per share
FierceBiotech 2025-12-12 2026 outlook: Biotech poised to outperform bear markets of ’21-24, analyst says
FierceBiotech 2025-12-11 Amgen obesity marketing leader Chris Boulton takes reins at metabolic biotech Prolynx
FierceBiotech 2025-12-11 Lilly's obesity triple threat smashes efficacy expectations in phase 3 but proves intolerable for some
FierceBiotech 2025-12-11 Rezolute's stock plunges 87% after hypoglycemia drug flunks pivotal phase 3 test
FierceBiotech 2025-12-11 FDA clears Lumosity brain training games as a prescription app for adult ADHD
FierceBiotech 2025-12-11 Zealand pens $2.5B oral cardiometabolic collab with fresh-faced Chinese biotech